T
Telum Therapeutics
The worrying and increasing development of bacterial resistance has led to the search of alternative substances to antibiotics
About Telum Therapeutics
Telum Therapeutics SL is a pioneering biotechnology company that focuses on developing innovative treatments to combat bacterial infections, particularly those resistant to traditional antibiotics. The company specializes in the use of phage-encoded lytic proteins, also known as enzybiotics, which are proteins derived from bacteriophages (viruses that infect bacteria) that can break down bacterial cell walls. This approach offers a promising alternative to conventional antibiotics, especially in the face of rising antibiotic resistance.
Read full description
Telum Therapeutics serves a global market, targeting healthcare providers, hospitals, and pharmaceutical companies that are in need of new solutions to treat multidrug-resistant bacterial infections. The company operates primarily in the drug discovery and biotechnology sectors, focusing on serious infections caused by Gram-negative bacteria such as Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa, as well as Gram-positive bacteria like Staphylococcus aureus and vancomycin-resistant Enterococci.
The business model of Telum Therapeutics revolves around the research and development (R&D) of these enzybiotics. The company progresses its discoveries from the initial research phase through preclinical trials, and eventually aims to bring these treatments to market. Revenue is generated through a combination of research grants, partnerships with larger pharmaceutical companies, and eventually, the commercialization of their proprietary treatments.
Telum Therapeutics is currently advancing several products in its development pipeline, each targeting different types of resistant bacterial infections. These products are in various stages of discovery and preclinical development, with patents filed to protect their innovative solutions.
In summary, Telum Therapeutics is at the forefront of addressing the critical issue of antibiotic resistance through its cutting-edge enzybiotic technology, aiming to bring new, effective treatments to the global healthcare market.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Noáin (Valle de Elorz)/Noain (Elortzibar), Spain
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 68.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Telum Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2026 | $21M | $84M | CDTI · Clave Capital · Invivo Partners · Sodena | ↗ |
| SEED✓Equity / VC | Sep 2024 | $1.1M | $4.6M | Invivo Partners · Navarra Tech Transfer · UN I + D + I Technology Transfer · CDTI Innvierte | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Telum Therapeutics is 510 monthly website visits, down 37.8% over the last three months. Telum Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Invivo Partners- NTNavarra Tech Transfer
UN I + D + I Technology Transfer
CDTI Innvierte
Series A5 investors entered at this stage
AMR Action Fund
CDTI
Clave Capital
Sodena
Inveready
Series B and later1 investor entered at this stage
ENISA
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Telum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Telum Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.